Targeting the Cellular Engines of Neurodegeneration
Biocient is developing small-molecule therapeutics designed to target mitochondria in aging neurons. Our lead program, BCNT-7, is currently in active preclinical development for Alzheimer's disease, with studies focused on disease-modifying effects and underlying pathology.
From discovery through preclinical development, our work depends on rigorous science and the people behind it. If you'd like to contribute, explore our open positions or share your CV with us.